Jason Pitofsky, SVP Controller at Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN), filed a Form 4 on November 6, 2026, disclosing option exercises and open-market sales of common stock that all occurred on November 4, 2026.

Key Highlights

  • Three option exercises: Pitofsky exercised non-qualified stock options for 905 shares at $492.00, 1,478 shares at $644.54, and 1,500 shares at $726.53, all on November 4, 2026.
  • Total shares sold: 4,062 shares of common stock were disposed of across seven sale transactions on November 4, 2026, at volume-weighted average prices ranging from approximately $939.57 to $950.76.
  • Remaining direct ownership: Following all reported transactions, Pitofsky directly held 4,272 shares of common stock.
  • Indirect holdings: The filing also reports 179 shares held indirectly by spouse and 48 shares held indirectly through a 401(k) plan.
  • Remaining options: After the exercises, Pitofsky retained 500 non-qualified stock options with an exercise price of $644.54 (expiring 12/08/2031) and 2,478 with an exercise price of $726.53 (expiring 12/16/2032).

Pitofsky's Option Exercises and Share Sales at Regeneron on November 4, 2026

According to the filing, Jason Pitofsky, identified as SVP Controller of Regeneron Pharmaceuticals, Inc., exercised three tranches of non-qualified stock options on November 4, 2026. The exercises covered 905 shares at an exercise price of $492.00 (expiring December 9, 2030), 1,478 shares at $644.54 (expiring December 8, 2031), and 1,500 shares at $726.53 (expiring December 16, 2032). The filing notes that each of these option awards "vested in four equal annual installments, commencing one year after the date of grant."

On the same date, the filing discloses that Pitofsky sold a total of 4,062 shares of common stock across seven separate transactions. Sale prices were reported as volume-weighted averages: 439 shares at $939.57, 575 shares at $940.46, 982 shares at $941.58, 1,215 shares at $942.31, 529 shares at $943.53, 108 shares at $944.22, 35 shares at $945.61, and 179 shares at $950.76. The filing states that the per-share figures for most of these tranches represent volume-weighted averages across price ranges within each tranche, and that full detail on individual sale prices will be provided upon request by the Commission staff, the company, or a security holder.

After all transactions reported in the filing, Pitofsky's direct beneficial ownership in common stock stood at 4,272 shares. Indirect holdings consisted of 179 shares held by his spouse and 48 shares held through a 401(k) plan, as reported in the filing. The remaining unexercised options totaled 2,978 shares across two tranches.

What Was Disclosed

The Form 4 filed November 6, 2026 covers Jason Pitofsky's exercise of three non-qualified stock option grants and the sale of 4,062 shares of Regeneron common stock on November 4, 2026, with resulting direct beneficial ownership of 4,272 shares.